Playback speed
10 seconds
ASH 2023 Insights: "PERSEUS Study - Daratumumab With VRd vs. VRd in NDMM Eligible for ASCT”
By
Integrity Continuing Education
FEATURING
Ola Landgren
By
Integrity Continuing Education
FEATURING
Ola Landgren
228 views
January 24, 2024
Login to view comments.
Click here to Login